Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIQ-AI Regulatory News (IQAI)

  • There is currently no data for IQAI

Grant Award

4 Sep 2019 07:00

RNS Number : 1074L
IQ-AI Limited
04 September 2019
 

 

IQ-AI Ltd

("IQ-AI" or the "Company")

 

Imaging Biometrics and Medical College of Wisconsin Awarded Grant

 

Imaging Biometrics™, LLC ("IB"), a subsidiary of IQ-AI Limited (LON:IQAI), in collaboration with the Medical College of Wisconsin ("MCW"), has received a $2.75 million, five-year grant award from the National Institutes of Health - National Cancer Institute. As a participant on this grant, IB will utilise the funding to assist in the translation of machine learned, scientifically validated algorithms to software solutions that provide new clinical insight on advanced brain tumor treatment and management.

 

 

David Smith, CEO of IB, commented, "Our grant and contract development work are important stimuli at Imaging Biometrics. This grant will provide income for the Company for the next 5 years, as well as, further catalyse the development of our quantitative imaging tools, enabling us to apply the result of this collaboration with MCW to our commercial products."

 

 

The Directors of the Company accept responsibility for the contents of this announcement.

 

-ENDS-

 

For further information, please contact:

IQ-AI Limited

Trevor Brown/Vinod Kaushal/Qu Li

Tel: 020 7469 0930

Peterhouse Capital Limited (Financial Adviser and Broker)

Lucy Williams/Fungai Ndoro

Tel: 020 7220 9797

 

About IQ-AI Ltd 

IQ-AI, Ltd, the parent company of StoneChecker® and Imaging Biometrics®, is focused on advanced and state of the art medical software and services. (IQ-AI.ltd). Imaging Biometrics develops and provides visualization and analytical solutions that enable clinicians to better diagnose and treat diseases with greater confidence. Through close collaboration with top researchers and clinicians, sophisticated advancements are translated into platform-independent software plug-ins which can extend the base functionality of workstations, imaging systems, PACS, or medical viewers. By design, IB's advanced visualization software seamlessly integrates into routine workflows. Please visit www.imagingbiometrics.com for further information.  

 

. 

About Imaging Biometrics™, LLC

Imaging Biometrics, a subsidiary of IQ-AI Limited (LON:IQAI), develops and provides visualization and analytical solutions that enable clinicians to better diagnose and treat diseases with greater confidence. Through close collaboration with top researchers and clinicians, sophisticated advancements are translated into platform-independent software plug-ins which can extend the base functionality of workstations, imaging systems, PACS, or medical viewers. By design, IB's advanced visualization software seamlessly integrates into routine workflows. For more information about Imaging Biometrics, visit the company's website at www.imagingbiometrics.com.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
STRLLFIRATIVIIA
Date   Source Headline
2nd Jan 201912:20 pmRNSHolding(s) in Company
13th Dec 20189:00 amRNSPrice Monitoring Extension
13th Dec 20187:00 amRNSStoneChecker 510k Update
11th Dec 20187:00 amRNSInstallation at Barrow Neurological Institute
28th Nov 20187:00 amRNSImaging Biometrics® Update
16th Nov 20187:00 amRNSFirst Commercial Sale of StoneChecker Software
22nd Oct 20187:00 amRNSIQ-AI files patent for Contrast-Free Imaging
4th Oct 20182:58 pmRNSResult of EGM and Change of Name
27th Sep 20187:00 amRNSIB announce agreement to develop a diagnostic tool
18th Sep 20187:00 amRNSProposed name change and notice of EGM
11th Sep 20189:00 amRNSDirector/PDMR Shareholding
11th Sep 20187:00 amRNSDirector/PDMR Shareholding
10th Sep 20187:00 amRNSHalf-year Report
6th Aug 20182:51 pmRNSHolding(s) in Company
6th Aug 20187:00 amRNSAppointment of CEO to the Operating Subsidiaries
1st Aug 20184:28 pmRNSPublication of a Prospectus
31st Jul 20183:54 pmRNSResult of AGM and GM
18th Jul 20181:24 pmRNSNon Regulatory - Vox Markets Podcast
18th Jul 20188:57 amRNSHolding(s) in Company
17th Jul 20187:00 amRNSECOG-ACRIN TO PROCESS CLINICAL TRIAL DATA USING IB
16th Jul 20187:00 amRNSPlacing, Notice of AGM and GM
2nd Jul 20188:34 amRNSMedimsight and IB Enter into Partnership
13th Jun 20187:00 amRNSImaging Biometrics and QMENTA announce partnership
9th May 20187:00 amRNSIB Software Chosen by St. Savvas Oncology Hospital
30th Apr 20184:25 pmRNSFinal Results
11th Apr 20187:00 amRNSIMAGING BIOMETRICS ANNOUNCES PARTNERSHIP
29th Mar 20182:52 pmRNSTotal Voting Rights
13th Mar 201810:54 amRNSTotal Voting Rights
13th Mar 20187:40 amRNSAcquisition of Imaging Biometrics
6th Mar 20187:00 amRNSStoneChecker signs agreement with Korea ISG
8th Feb 20181:44 pmRNSPotential Acquisition
8th Feb 20189:05 amRNSSecond Price Monitoring Extn
8th Feb 20189:00 amRNSPrice Monitoring Extension
11th Dec 20177:00 amRNSCE marked release of StoneChecker® Software
6th Nov 20174:40 pmRNSSecond Price Monitoring Extn
6th Nov 20174:35 pmRNSPrice Monitoring Extension
26th Oct 20177:00 amRNSUpdate on Business Operations
9th Oct 20172:33 pmRNSHolding(s) in Company
18th Sep 20177:00 amRNSUpdate on Product Development and Warrant Exercise
4th Sep 20179:49 amRNSStone Checker Update
30th Aug 201710:04 amRNSHolding(s) in Company
17th Aug 20177:01 amRNSDirector Dealings
17th Aug 20177:00 amRNSHalf-year Report
14th Aug 201710:12 amRNSHolding(s) in Company
27th Jul 20174:40 pmRNSSecond Price Monitoring Extn
27th Jul 20174:35 pmRNSPrice Monitoring Extension
11th Jul 20177:00 amRNSUpdate on Operations
3rd Jul 20177:00 amRNSConversion of Convertible Loan Notes into Equity
27th Jun 20174:40 pmRNSSecond Price Monitoring Extn
27th Jun 20174:35 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.